This is a wonderful prelude to the start of the Nature's Wealth clinical
trial starting in January where we will test the regimen for fibromyalgia,
an untreatable disorder. The 3 month study will include a placebo group, a
group given only rhea extract, and a group given rhea extract, detoxifiers,
and other nutritional factors (a high potency vitamin-antioxidant
supplement).
Since the core product (rhea extract) is on the market as a dietary
supplement already, and has been for 2 years, we already have a very good
sense of the expected results.
This is the beginning of the justification for genuine organic standards so
these patients can reduce their toxin load in the food they eat.
Donna Fezler
http://www.rhealiving.com
Pioneering research in the role of environmental toxins in autoimmune
disorders.
http://www.natureswealth.com
Illness from low levels of environmental chemicals: relevance to chronic
fatigue syndrome and fibromyalgia [In Process Citation]
Bell, I. R.
Baldwin, C. M.
Schwartz, G. E.
American Journal of Medicine Vol. 105, issue 3A, 74S-82S, 1998
Abstract
This article summarizes (1) epidemiologic and clinical data on the symptoms
of maladies in association with low-level chemicals in the environment,
i.e., environmental chemical intolerance (CI), as it may relate to chronic
fatigue syndrome (CFS) and fibromyalgia; and (2) the olfactory-limbic neural
sensitization model for CI, a neurobehavioral synthesis of basic and
clinical research.
Severe CI is a characteristic of 20-47% of individuals with apparent CFS
and/or fibromyalgia, all patients with multiple chemical sensitivity (MCS),
and approximately 4- 6% of the general population. In the general
population, 15-30% report at least minor problems with CI. The levels of
chemicals reported to trigger CI would normally be considered nontoxic or
subtoxic.
However, host factors--e.g., individual differences in susceptibility to
neurohormonal sensitization (amplification) of endogenous responses-- may
contribute to generating a disabling intensity to the resultant multisystem
dysfunctions in CI. One site for this amplification may be the limbic system
of the brain, which receives input from the olfactory pathways and sends
efferents to the hypothalamus and the mesolimbic dopaminergic [reward]
pathway. Chemical, biologic, and psychological stimuli can initiate and
elicit sensitization. In turn, subsequent activation of the sensitized
limbic and mesolimbic pathways can then facilitate dysregulation of
behavioral, autonomic, endocrine, and immune system functions. Research to
date has demonstrated the initiation of neurobehavioral sensitization by
volatile organic compounds and pesticides in animals, as well as
sensitizability of cardiovascular parameters, beta-endorphin levels, resting
EEG alpha- wave activity, and divided-attention task performance in persons
with CI. The ability of multiple types of widely divergent stimuli to
initiate and elicit sensitization offers a new perspective on the search for
mechanisms of illness in CFS and fibromyalgia with CI.
To Unsubscribe: Email majordomo@ces.ncsu.edu with "unsubscribe sanet-mg".
To Subscribe to Digest: Email majordomo@ces.ncsu.edu with the command
"subscribe sanet-mg-digest".